[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


2. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • While whole abdominal radiotherapy has a limited role in early-stage uterine papillary serous carcinoma (UPSC) and clear cell carcinoma (CC), there may be a role for postoperative chemotherapy and volume-directed radiotherapy in both early-stage UPSC and CC.
  • In the setting of optimally debulked advanced-stage disease, a combination of radiation and chemotherapy may be indicated.
  • CONCLUSIONS: UPSC and CC are managed similarly since sufficient data to separate treatment recommendations are lacking.
  • Because both histologies are associated with a high rate of recurrence, adjuvant therapy is recommended even in women with early-stage disease.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Female. Gynecologic Surgical Procedures. Humans. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


3. Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, Moerman P, Vergote I, Amant F: Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer; 2009 Jul 21;101(2):244-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
  • BACKGROUND: To investigate the value of neoadjuvant chemotherapy (NACT), followed by interval debulking surgery (IDS), in endometrial cancer with transperitoneal spread (stage IV).
  • Histopathological subtypes were as follows: serous (90%), clear cell (3%) and endometrioid (6%) carcinoma.
  • The median progression-free survival and overall survival times were 13 and 23 months, respectively.Histopathological features of chemoresponse in both uterus and omentum were related to a better PFS (P=0.017, hazard ratio (HR) =0.785) and overall survival (P=0.014, HR=0.707).
  • CONCLUSION: The use of NACT resulted in a high rate (80%) of optimal IDS for the treatment of endometrial cancer with transperitoneal spread.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):211-7 [17239941.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):710-8 [17182981.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):160-3 [17490737.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):190-3 [17825394.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):92-9 [11277657.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):454-8 [12366662.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):74-7 [12488296.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):653-8 [15196860.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):327-31 [2351315.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):237-40 [8314145.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):123-7 [8690284.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):56-60 [9345357.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):140-4 [10094895.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:273-7 [16515603.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):986-90 [16803473.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):926-34 [17397905.001]
  • (PMID = 19568245.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2720217
  •  go-up   go-down


Advertisement
4. Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou CA, Markaki S, Dimopoulos MA: Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. Eur J Gynaecol Oncol; 2005;26(6):627-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
  • The aim of this study was to investigate the activity and safety of paclitaxel/carboplatin chemotherapy as the only adjuvant treatment in patients with surgically resected UPSC and UCCC.
  • No patient had residual disease after surgery and none underwent pre- or post-chemotherapy irradiation.
  • Mean time to recurrence was 16.9 months.
  • CONCLUSION: Chemotherapy with paclitaxel plus carboplatin is feasible and possibly prevents distant metastasis when used as adjuvant in UPSC and UCCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Survival Analysis. Treatment Outcome

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398224.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. McCluggage WG, Bryson C, Lamki H, Boyle DD: Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy. Int J Gynecol Pathol; 2000 Jul;19(3):276-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign, borderline, and malignant endometrioid neoplasia arising in endometriosis in association with tamoxifen therapy.
  • Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis.
  • This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen.
  • There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus.
  • The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
  • [MeSH-major] Adenocarcinoma / chemically induced. Carcinoma, Endometrioid / chemically induced. Endometrial Neoplasms / chemically induced. Endometriosis / pathology. Ovarian Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Estrogen Antagonists / adverse effects. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907178.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


6. Boran N, Akdag D, Halici F, Tulunay G, Turan T, Bozok S, Erdogan Z, Kose MF: A retrospective analysis of the diameter of metastatic lymph nodes in apparently early stage endometrial cancer. Tumori; 2008 Sep-Oct;94(5):681-5
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND STUDY DESIGN: Among 700 cases with endometrial cancer, 27 cases with disease clinically limited to the uterus in the laparotomy and found to have retroperitoneal node metastasis after pathologic examination were included in this study.
  • By sampling or selective para-aortic and/or pelvic lymphadenectomy, some of the nodes might go undiagnosed, and such understaged cases cannot take adjuvant therapy (chemotherapy-radiotherapy).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / secondary. Adult. Aged. Aorta. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovariectomy. Pelvis. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112940.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Hentati D, Belghith B, Kochbati L, Driss M, Maalej M: Clear cell carcinoma of the uterus. Tunis Med; 2010 Apr;88(4):230-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the uterus.
  • The mean age at diagnosis was 64 years (50 to 84 yers).
  • Two patients with abdomino-pelvic recurrences progressed despite the association of surgery, radiation therapy and chemotherapy.
  • CONCLUSION: Extrauterine extension is frequent at diagnosis and not correlated to classical risk factors observed in endometrioid carcinoma.
  • A comptlete surgical staging is necessary for adjuvant treatment.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20446254.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie meĢdicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


8. Shigemitsu A, Furukawa N, Koike N, Kobayashi H: Endometrial cancer diagnosed by the presence of bone metastasis and treated with zoledronic Acid: a case report and review of the literature. Case Rep Oncol; 2010 Sep;3(3):471-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography revealed an enlarged uterus; the patient consequently consulted a gynecologist.
  • Histological sections of an endometrial biopsy showed endometrioid adenocarcinoma.
  • A moderately differentiated endometrioid adenocarcinoma was expressed in the corpus.
  • Histopathological examination of the bone biopsy also revealed adenocarcinoma.
  • The final diagnosis was stage IVB endometrial cancer with bone and lung metastasis.
  • Good pain relief was achieved due to chemotherapy.
  • However, 2 months after completion of the chemotherapy, the patient was administered zoledronic acid because her hip pain had gradually increased.
  • Radiotherapy was then given for the right ischial metastasis after the ninth course of zoledronic acid therapy because the metastasis site had increased and the possibility of a pathological fracture had risen.
  • However, the patient died 21 months after the initial treatment because of disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S30-6 [14659141.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):142-6 [1592280.001]
  • [Cites] Clin Exp Metastasis. 2007;24(2):87-92 [17364220.001]
  • [Cites] J Foot Ankle Surg. 2005 Nov-Dec;44(6):462-5 [16257676.001]
  • [Cites] BJU Int. 2009 Mar;103(5):620-4 [18990143.001]
  • [Cites] J Gynecol Oncol. 2009 Jun;20(2):67-71 [19590716.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2779-81 [8194019.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):108-14 [2227582.001]
  • [Cites] Ann Surg. 1940 Jul;112(1):138-49 [17857618.001]
  • (PMID = 21611145.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100269
  • [Keywords] NOTNLM ; Bisphosphonates / Bone metastasis / Endometrial cancer
  •  go-up   go-down


9. Silva EG, Deavers MT, Bodurka DC, Malpica A: Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol; 2006 Jan;25(1):52-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?
  • Low-grade endometrioid carcinomas, either of the endometrium or the ovaries, usually have an excellent prognosis.
  • The association of this type of tumor with undifferentiated carcinoma is rare.
  • The endometrioid carcinoma involved the endometrium in 14 cases, the endometrium and 1 or both ovaries in 9 cases, and the ovaries in 2 cases.
  • Undifferentiated carcinoma associated with low-grade endometrioid carcinoma was found at presentation in 19 grade 1 or 2 endometrioid carcinomas: 15 in the endometrium and 5 in the ovary.
  • Undifferentiated carcinoma was found after resection of low-grade endometrioid carcinoma in six cases, involving the retroperitoneum, pelvis, vagina, or liver.
  • Twenty-two patients received additional therapy as follows: chemotherapy (), radiotherapy (), and tamoxifen ().
  • In four cases, the diagnosis was made recently, with short follow-ups of 3 and 4 months.
  • Foci of undifferentiated carcinoma may be confused with solid endometrioid adenocarcinoma erroneously leading to the diagnosis of a grade 3 or a significantly less aggressive grade 2 endometrioid carcinoma.
  • The recognition of undifferentiated carcinoma in an otherwise low-grade endometrioid adenocarcinoma is extremely important because it indicates aggressive behavior.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Transformation, Neoplastic. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Pathol. 2006 Jul;25(3):304
  • (PMID = 16306785.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature.
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.
  • CONCLUSIONS: This is, to our knowledge, the first report of malignant mixed Mullerian tumor of the uterus with an AFP-producing hepatoid adenocarcinoma component.

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


11. Itoh K, Shiozawa T, Shiohara S, Ashida T, Konishi I: Endometrial carcinoma in septate uterus detected 6 months after full-term delivery: case report and review of the literature. Gynecol Oncol; 2004 Apr;93(1):242-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma in septate uterus detected 6 months after full-term delivery: case report and review of the literature.
  • We present the case of a 39-year-old woman with endometrial carcinoma in the septate uterus detected 6 months after normal delivery.
  • A histological diagnosis of endometrial carcinoma was made based on examination of frozen sections from the hysterectomy specimen, and bilateral salpingo-oophorectomy and pelvic/para-aortic lymphadenectomy were also performed.
  • Histological examination revealed G3 endometrioid adenocarcinoma with squamous differentiation, which arose in the septum of the uterus and deeply invaded the myometrium.
  • The patient received postoperative chemotherapy and is healthy with no evidence of disease 3 years after the treatment.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15047244.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


12. Toyoda H, Hirai T, Ishii E: Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int; 2000 Oct;50(10):847-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium.
  • The postoperative serum AFP value transiently decreased with chemotherapy, however, lung metastases were found and the patient died 12 months following surgery.
  • The resected uterus had a necrotic tumor, 6 x 5 x 4 cm in size, filling the endometrial cavity, characterized by exophytic growth with infiltration in the myometrium.
  • Histologically, the tumor was composed of the main medullary carcinoma area with microcysts and admixed small areas of well-differentiated endometrioid adenocarcinoma, accompanied by a smooth transition with one another.
  • Although the histogenesis remains controversial, we assume the hypothesis that the tumor may arise in the endometrium per se in association with abnormal differentiation of muellerian duct elements.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107058.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


13. Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H: Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol; 2001;22(3):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations.
  • BACKGROUND: To determine the effectiveness of medroxyprogesterone acetate therapy for women with endometrial adenocarcinoma who wish to preserve their uterus.
  • STUDY DESIGN: Fifteen patients with endometrial carcinoma (12 with grade 1 endometrioid adenocarcinoma.
  • 2 with grade 2 adenocarcinoma and 1 with adenoacanthoma) were treated with high-dose medroxyprogesterone acetate alone as primary therapy and their clinical responses evaluated.
  • RESULTS: Seven of the 12 cases (58%) with grade I adenocarcinoma and one of the two (50%) with grade 2 carcinoma responded initially to medroxyprogesterone acetate.
  • The median length of treatment required for regression was 29 weeks.
  • Thirteen patients are alive without evidence of disease as of December 1999 (10 to 146 months, median; 4 years and 11 months) and one is continuing medroxyprogesterone acetate therapy as a final follow-up.
  • CONCLUSION: Treatment of endometrial carcinoma with high-dose medroxyprogesterone acetate could be an alternative to hysterectomy, although the successful rate is limited.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Fertility. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Adult. Female. Humans. Japan. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11501776.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


14. Wani Y, Notohara K, Tsukayama C: Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):346-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.
  • Mesonephric adenocarcinoma (MA) is a rare tumor of the female genital tract, mainly in the cervix and vagina, which is usually associated with mesonephric remnants or mesonephric hyperplasia.
  • In the uterus corpus, MA is as rare as mesonephric structures, and only a few cases have been previously reported.
  • Abdominal computed tomography scan confirmed a uterine tumor measuring 8.6 cm.
  • The most striking pattern consisted of large sheets of small round tubules, often with densely eosinophilic secretions in the lumen.
  • In addition, the ductal pattern simulating endometrioid adenocarcinoma was also noted.
  • A mixture of tubular and ductal patterns, most predominantly seen, formed more complex tubules and cribriform structures.
  • Other elements consisted of a retiform pattern, serous adenocarcinoma-like papillary budding, and glomeruloid morphology.
  • Adjuvant chemotherapy was begun for the patient, who is alive with disease 28 months later.
  • We review the previously published cases of MA and discuss the principal differential diagnosis of MA in the uterine corpus.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580312.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


15. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • All patients were treated surgically followed by chemotherapy with a 3-year survival rate of 66.7% (8/12).
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


16. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • RESULTS: The median age at diagnosis was 49 years (range, 28-73 years).
  • Of 25 patients examined by CT/MRI, pelvic masses were found in 13 cases and enlarged uterus in 11 cases.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • Postoperatively, 26 patients (60.5%) received adjuvant chemotherapy alone, 12 had chemotherapy plus radiotherapy, only one patient had radiation alone and the remaining 4 cases received no adjuvant treatment.
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • Recurrence developed in 15 patients (34.9%).
  • It was showed by univariate analysis that lower CA125 level, early FIGO stage, and adjuvant chemotherapy plus radiotherapy significantly and positively affect the 5-year survival rates, while only early FIGO stage and chemotherapy plus radiotherapy were revealed by multivariate analysis as independent prognostic factors.
  • Surgical treatment alone may be enough for early stage patients.
  • Chemotherapy plus radiotherapy may be necessary for advanced stage patients.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Proteins / metabolism. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


17. Cohn DE, Resnick KE, Ramirez NC, Morrison CD: Advanced endometrial cancer with serous metastasis in a 17-year-old. Gynecol Oncol; 2006 May;101(2):356-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 17-year-old presented with menorrhagia requiring blood transfusion and a transvaginal ultrasound demonstrated a 31 mm endometrial stripe within a bulky uterus.
  • Endometrial curettage revealed a grade 2 endometrioid adenocarcinoma.
  • The patient desired definitive surgical management for her disease; a stage IIIC endometrial cancer with focal low-grade serous carcinoma among a grade 2 endometrioid carcinoma was noted to be superficially myoinvasive.
  • Multiple pelvic lymph nodes had evidence of metastatic serous adenocarcinoma.
  • Platinum-based chemotherapy was administered, and the patient is without disease 24 months following therapy.
  • This information is critically important when counseling a woman regarding conservative management of endometrial adenocarcinoma with the interest of preservation of her fertility.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499956.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Arck PC, Hertwig K, Hagen E, Hildebrandt M, Klapp BF: Pregnancy as a model of controlled invasion might be attributed to the ratio of CD3/CD8 to CD56. Am J Reprod Immunol; 2000 Jul;44(1):1-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROBLEM: Pregnancy can be considered as a model of successfully controlled tissue invasion.
  • METHOD OF STUDY: Decidual tissue from first trimester normal pregnancies (NP; n = 15) and abortion (AB; n = 12), endometrial samples from premenopausal women (NE; n = 8), and endometrioid adenocarcinoma (EA; n = 8) were examined by immunohistochemistry using monoclonal antibody against large spectrum cytokeratin, and against the receptors CD3, CD8, CD56 and CD68, respectively.
  • The decrease of CD56 positive cells in endometrioid adenocarcinoma was statistically significant.
  • Studying different pathological situations in the uterus, such as malignancies or ectopic pregnancies, might help us to understand the mechanisms involved in the maintenance of pregnancy.
  • [MeSH-minor] Abortion, Induced. Abortion, Spontaneous / immunology. Adenocarcinoma / immunology. Adult. Antigens, CD3 / analysis. Antigens, CD56 / analysis. Antigens, CD8 / analysis. Decidua / cytology. Decidua / immunology. Endometrial Neoplasms / immunology. Endometrium / immunology. Female. Humans. Immunohistochemistry. Lymphocyte Count. Middle Aged. Pregnancy Trimester, First / immunology. Premenopause / immunology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976806.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD56; 0 / Antigens, CD8
  •  go-up   go-down


19. Ichikawa Y, Takano K, Higa S, Tanabe M, Wada A, Sugita M, Tsunoda H, Nishida M: Endometrial carcinoma coexisting with pregnancy, presumed to derive from adenomyosis: a case report. Int J Gynecol Cancer; 2001 Nov-Dec;11(6):488-90
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative magnetic resonance imaging (MRI) revealed a cystic mass attached to the uterus, with a papillary projection on the wall of the mass.
  • The patient underwent complete surgical extirpation and five postoperative courses of adjuvant chemotherapy, given that the tumor contents had leaked into the peritoneal cavity when the capsule of the tumor ruptured intraoperatively.
  • Microscopic examination revealed an endometrioid adenocarcinoma in the muscular layer close to the uterine serosa that was presumed to derive from adenomyosis.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Endometriosis / complications. Endometriosis / pathology. Endometriosis / therapy. Female. Humans. Magnetic Resonance Imaging. Pregnancy

  • Genetic Alliance. consumer health - Adenomyosis.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11906554.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ettinger B, Kenemans P, Johnson SR, Mol-Arts M, Van Os S, Seifert W, Verweij PJ, Cummings SR: Endometrial effects of tibolone in elderly, osteoporotic women. Obstet Gynecol; 2008 Sep;112(3):653-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Postmenopausal women (N=3,519) aged 60-85 years (mean 68 years) with a uterus and with osteoporosis were randomly assigned to receive tibolone orally, 1.25 mg per day, or identical placebo.
  • A marginal increase in grade 1 endometrioid adenocarcinoma (P=.06 compared with placebo) was found among women receiving tibolone.
  • CONCLUSION: Tibolone treatment during 3 years minimally increased endometrial thickness, hyperplastic polyps, endometrial carcinoma, and vaginal bleeding.
  • [MeSH-major] Carcinoma, Endometrioid / chemically induced. Endometrial Neoplasms / chemically induced. Estrogen Replacement Therapy / adverse effects. Norpregnenes / adverse effects. Osteoporosis, Postmenopausal / drug therapy
  • [MeSH-minor] Aged. Bone Density Conservation Agents / pharmacology. Endometrium / drug effects. Endometrium / pathology. Female. Humans. Hyperplasia / chemically induced. Metrorrhagia / chemically induced. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18757665.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Norpregnenes; FF9X0205V2 / tibolone
  •  go-up   go-down


21. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol; 2005 Jun;97(3):924-7
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
  • BACKGROUND: Intrauterine progesterone therapy potentially provides a simple alternative treatment for women with Stage I Grade I endometrial cancers who are at high risk for surgery.
  • CASES: Four women had Stage I grade 1 endometrial adenocarcinoma with positive progesterone receptor.
  • One of three women who did not respond to treatment subsequently had a vaginal hysterectomy, which showed endometrial cancer with superficial myometrial invasion.
  • CONCLUSION: This report raises doubts about the effectiveness of intrauterine progesterone therapy as a definitive alternative for the treatment of early endometrial cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Levonorgestrel / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Routes. Female. Humans. Middle Aged. Uterus

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943993.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 5W7SIA7YZW / Levonorgestrel
  • [Number-of-references] 13
  •  go-up   go-down


22. Albores-Saavedra J, Martinez-Benitez B, Luevano E: Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol; 2008 Jul;27(3):333-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report 5 polypoid high-grade neuroendocrine carcinomas of the uterus, 2 small cell carcinomas of the endometrium, and 3 large cell neuroendocrine carcinomas, 2 from the cervix and 1 from the endometrium.
  • The 2 small cell carcinomas of the endometrium arose from and were confined to endometrial polyps, one of which also showed foci of endometrioid adenocarcinoma.
  • All 5 patients were treated by radical hysterectomy and 4 received adjuvant chemotherapy.
  • All patients are alive and disease-free from 9 months to 7 years after treatment (mean survival, 47 months).
  • Our findings suggest that stage of disease and a polypoid gross feature are the best predictors for outcome in small cell carcinomas and large cell neuroendocrine carcinomas of the uterus.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580310.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ: Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol; 2002 Apr;186(4):651-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrauterine progesterone treatment of early endometrial cancer.
  • OBJECTIVE: Our purpose was to assess the feasibility of using a progesterone-containing intrauterine device (IUD) to treat presumed Federation Internationale Gynecologie et d'Obstetrique (FIGO) stage IA, grade 1 endometrioid cancer in women at high risk for perioperative complications.
  • STUDY DESIGN: Candidates were women with American Society of Anesthesiologists class III or IV grade 1 endometrioid cancer and no imaging evidence of myometrial invasion.
  • Fourteen consented to participation; one was excluded at the time of IUD placement (grade 2 disease identified) and one was lost to follow-up.
  • CONCLUSION: Intrauterine progesterone appears to eradicate some cases of presumed stage IA, grade 1 endometrioid cancer in women at high risk for perioperative morbidity.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Progesterone / administration & dosage. Uterus / drug effects
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Biopsy. Curettage. Drug Administration Routes. Female. Humans. Hysteroscopy. Intrauterine Devices, Medicated. Magnetic Resonance Imaging. Menopause. Middle Aged. Neoplasm Invasiveness. Ultrasonography

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11967486.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


24. Zaino R, Whitney C, Brady MF, DeGeest K, Burger RA, Buller RE: Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol; 2001 Nov;83(2):355-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is often unclear whether this represents synchronous primary tumors or metastasis from endometrium to ovary, or from ovary to endometrium; consequently, staging, therapy, and expected outcome are uncertain.
  • All were initially treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy, and staging laparotomy, with radiation and chemotherapy left to the discretion of the treating physician and patient.
  • Sixty-four (86%) patients had endometrioid carcinomas in both the endometrium and the ovary, and endometriosis was found in the ovary of 23 (31%) patients.
  • There was concordance between the histologic grade of the tumor in the ovary and the uterus in 51 (69%) patients.
  • The presence of metastasis discriminated two groups of patients that experienced different probabilities of recurrence within 5 years: 10.0% (95% CI: 4.32-21.3%) for those with tumors confined to the uterus and ovary and 27.1% (95% CI: 13.0-48.5%) for those with metastasis (hazard ratio = 4.6, P = 0.006).
  • CONCLUSION: The prognosis for women with simultaneously detected carcinomas in the uterus and ovary with gross disease confined to the pelvis is surprisingly good, particularly for those with disease microscopically limited to the uterus and ovary or of low histologic grade.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11606097.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 12482; United States / NCI NIH HHS / CA / CA 12534; United States / NCI NIH HHS / CA / CA 13630; United States / NCI NIH HHS / CA / CA 15975; United States / NCI NIH HHS / CA / CA 16386; United States / NCI NIH HHS / CA / CA 16938; United States / NCI NIH HHS / CA / CA 19502; United States / NCI NIH HHS / CA / CA 21720; United States / NCI NIH HHS / CA / CA 21946; United States / NCI NIH HHS / CA / CA 23501; United States / NCI NIH HHS / CA / CA 23765; United States / NCI NIH HHS / CA / CA 37535; United States / NCI NIH HHS / CA / CA 37569; United States / NCI NIH HHS / CA / CA 40296
  • [Publication-type] Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


25. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol; 2008 Sep;110(3):345-53
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Records of 62 patients with invasive EOC who underwent fertility-sparing surgery, defined as the preservation of ovarian tissue in one or both adnexa and the uterus, between May 1990 and October 2006, were retrospectively reviewed.
  • Forty-eight patients received platinum-based adjuvant chemotherapy (mean 4.6 cycles, range 1-9 cycles).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Disease-Free Survival. Female. Gynecologic Surgical Procedures / adverse effects. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Invasiveness. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2009 Mar;112(3):673-4; author reply 674 [18986689.001]
  • (PMID = 18586310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Yasuda M, Matsui N, Kajiwara H, Osamura RY, Miyamoto T, Murakami M, Shinozuka T, Itoh J: Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathol Int; 2004 Jun;54(6):451-6
Genetic Alliance. consumer health - Malignant germ cell tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation.
  • A 31-year-old woman was treated for atypical endometrial hyperplasia (AEH) with high-dose medroxyprogesterone acetate (MPA) therapy to preserve fertility.
  • The AEH was found by repeated cytologic and histologic examinations to have completely disappeared with the therapy, but 3 years after her last follow up she required emergency surgery to treat severe genital bleeding.
  • The hysterectomied uterus consisted mostly of poorly differentiated adenocarcinoma, G3 endometrioid type.
  • Recurrent AEH had undergone malignant transformation, resulting in the development of well- and poorly differentiated adenocarcinoma and tumor exhibiting germ-cell-like differentiation.
  • The AEH before MPA therapy and the recurrent tumors had genetically different characteristics based on evidence of a loss of heterozygosity, detected at D8S1132 (chromosomal locus, 8q22.1) in the latter but not in the former, by analysis of genetic alterations using microsatellite markers.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Hyperplasia / drug therapy. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / pathology. Germinoma / secondary. Medroxyprogesterone Acetate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15144406.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / GPI-Linked Proteins; 0 / Isoenzymes; 0 / alpha-Fetoproteins; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.1.3.1 / alkaline phosphatase, placental
  •  go-up   go-down


27. Yarali H, Bozdag G, Aksu T, Ayhan A: A successful pregnancy after intracytoplasmic sperm injection and embryo transfer in a patient with endometrial cancer who was treated conservatively. Fertil Steril; 2004 Jan;81(1):214-6
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe a patient with polycystic ovary syndrome (PCOS) conceiving with intracytoplasmic sperm injection (ICSI) and embryo transfer after conservative treatment of early stage endometrial cancer.
  • SETTING: Tertiary center for assisted reproductive technologies.A 32-year-old woman with PCOS, primary infertility of 4 years duration, and grade 1 endometrioid endometrial cancer.
  • High-dose progestin treatment and ICSI and embryo transfer.
  • CONCLUSION(S): Conservative uterus-preserving treatment may be considered in patients with early stage endometrial cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Embryo Transfer. Endometrial Neoplasms / drug therapy. Sperm Injections, Intracytoplasmic / methods
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Cesarean Section. Female. Humans. Magnetic Resonance Imaging. Medroxyprogesterone Acetate / therapeutic use. Megestrol Acetate / therapeutic use. Pregnancy. Pregnancy Outcome. Progesterone / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14711571.001).
  • [ISSN] 0015-0282
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 4G7DS2Q64Y / Progesterone; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down






Advertisement